Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

Randomized, Double-blind, Parallel-group, Phase 1 Study

This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.

Inclusion Criteria:

• diagnosed with active ankylosing spondylitis
• BASDAI score ≥ 4 and visual analogue scale(VAS) score of spinal pain ≥ 4

Exclusion Criteria:

• have total ankylosing of spine
• have allergies to infliximab
• serious infection